Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Innovent Biologics (IVBXF)
OTHER OTC:IVBXF
Innovent Biologics (IVBXF) Stock Price & Analysis
27 Followers
IVBXF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.51 - $6.41
Previous Close$4.6
Volume3.21K
Average Volume (3M)145.73K
Market Cap
$7.43B
Enterprise Value$6.84B
Total Cash (Recent Filing)¥7.03B
Total Debt (Recent Filing)¥2.77B
Price to Earnings (P/E)-51.7
Beta0.30
Next Earnings
Aug 21, 2024EPS Estimate
-$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume145,734
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.06Price Target Upside53.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
10.42% Mutual Funds
7.06% Other Institutional Investors
82.52% Public Companies and
Individual Investors
IVBXF FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was $3.51 and its highest was $6.41 in the past 12 months.
What is Innovent Biologics’s market cap?
Currently, no data Available
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Aug 21, 2024 which is in 116 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Mar 20, 2024. The company reported -$0.078 earnings per share for the quarter, beating the consensus estimate of -$0.097 by $0.018.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is -$0.05.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,622,682,900 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of -$0.078 in its last earnings report, beating expectations of -$0.097. Following the earnings report the stock price went up 0.6%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in IVBXF
---
Innovent Biologics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.06 (53.48% Upside)
$7.06 (53.48% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.56%
12-Months-Change
Fundamentals
Return on Equity
-8.63%
Trailing 12-Months
Asset Growth
14.95%
Trailing 12-Months
Company Description
Innovent Biologics
Innovent Biologics, Inc. is an investment company, which engages in the development and manufacture of biopharmaceutical products. Its products include sintilimab (IBI-308), a novel PD-1 antibody; IBI-305, the bevacizumab (Avastin) biosimilar; IBI-301, the rituximab (MabThera/Rituxan) biosimilar; and IBI-303, the (Humira) biosimilar. The company was founded by De Chao Yu, Kevin Chen, and Scott M. Wheelwright on April 28, 2011 and is headquartered in Suzhou, China.
---
IVBXF Stock 12 Months Forecast
Average Price Target
$7.06
▲(53.48% Upside)
Technical Analysis
Best Analysts Covering IVBXF
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
+6.08%
reiterated a buy rating 2 months ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +6.08% per trade.
---